

香港聯合交易所有限公司

(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

通告 CIRCULAR

香港聯合交易所有限公司竭力確保其提供之資料準確可靠，惟不保證該等資料絕對正確，亦不對由於任何資料不確或遺漏所引之損失或損害負上責任(不論是民事侵權行為責任或合約責任或其他)。

The Stock Exchange of Hong Kong Limited endeavours to ensure the accuracy and reliability of the information provided, but does not guarantee its accuracy and accepts no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

FOR REFERENCE ONLY

Subject : Display of Previous Closing Price of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code 2196) and Fosun International Limited (stock code 656) on OTP-C for the Preferential Offering of the H shares of Shanghai Henlius Biotech, Inc. on Ex-All Date, 2 September 2019

Enquiry Tel : Mr. Leo Cheung (Tel: 2840 3450) or Ms. Grace Leung (Tel: 2840 3797)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharmaceutical") and Fosun International Limited ("Fosun International") jointly announced a spin-off proposal for a separate listing of Shanghai Henlius Biotech, Inc. ("Shanghai Henlius") (the "Proposed Spin-Off"). Qualifying Fosun Pharmaceutical H shareholders and qualifying Fosun International shareholders will be entitled to apply for Shanghai Henlius H shares on the following basis (the "Preferential Offering"):-

For Qualifying Fosun Pharmaceutical H shareholders:-

- 1 Shanghai Henlius H share for every 132 H shares of Fosun Pharmaceutical held on the record date

For Qualifying Fosun International shareholders:-

- 1 Shanghai Henlius H share for every 2,041 shares of Fosun International held on the record date

According to the timetable for the Preferential Offering, Fosun Pharmaceutical's H shares (stock code: 2196) and Fosun International's shares (stock code: 656) will be marked "ex-all" on 2 September 2019, the Ex-All Date.

Given that the exact value of the H shares of Shanghai Henlius is not known, the Exchange will display "N/A" in the "PRV CLOSE" field of each of Fosun Pharmaceutical's and Fosun International's OTP-C stock page on 2 September 2019, the Ex-All Date in accordance with the OTP-C standard practice. The unadjusted previous closing price for each of Fosun Pharmaceutical and Fosun International will be displayed in the respective free text field.

.../2



Shareholders, investors and market participants should read the joint announcements issued by Fosun Pharmaceutical and Fosun International in full including the terms and conditions of the Proposed Spin-Off and the Preferential Offering in dealing with Fosun Pharmaceutical's H shares and Fosun International's shares. If they are in doubt, they should consult their professional adviser(s).

Charles Woo
Vice President
Listing Department